Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02144038

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma Clinical Trial

Official title:
A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Clinical Trial Summary

This is a Phase Ib/II study with the primary purpose of the Phase Ib part being to estimate the MTD and/or recommended phase 2 dose (RP2D) of the combination of LGH447 and BYL719 when administered orally to adult patients with relapsed and refractory multiple myeloma. Once the MTD and/or RP2D is determined for the combination of LGH447 and BYL719, additional patients will be enrolled in the Phase II part to determine whether the combination of LGH447 and BYL719 exhibits improved anti-multiple myeloma activity compared to single agent LGH447. This trial never made it to the Phase II part of the this trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02144038
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date July 23, 2014
Completion date October 28, 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06050512 - Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Phase 1
Terminated NCT03683277 - IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic Phase 2
Recruiting NCT04155749 - Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Phase 1
Completed NCT03029234 - Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Phase 3
Recruiting NCT05530421 - Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03559764 - Study of BCMA CAR-T in Multiple Myeloma Early Phase 1
Terminated NCT00664378 - Efficacy Study of CYT997 in Multiple Myeloma Phase 2
Terminated NCT03710915 - A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT02223598 - A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Phase 1
Completed NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting NCT03661554 - BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Early Phase 1